VPC
IMCR icon

Vestal Point Capital’s Immunocore IMCR Stock Holding History

Vestal Point Capital’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.1M Sell
1,800,000
-966,868
-35% -$28.6M 1.34% 26
2026
Q1 		$83.4M Buy
2,766,868
+2,181,868
+373% +$70.6M 2.33% 12
2025
Q4 		$20.3M Buy
+585,000
New +$20.7M 0.69% 37

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Vestal Point Capital's IMCR Position: Q2 2026 in Review

Vestal Point Capital reduced its Immunocore (IMCR) stake by 35% in Q2 2026, selling an estimated $28.6M and leaving 1,800,000 shares worth $57.1M. The position accounts for 1.34% of the portfolio, ranked #26.

Vestal Point Capital first reported a position in IMCR in Q4 2025 and has held it in 3 quarters since. The position peaked at $83.4M in Q1 2026. 136 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • Vestal Point Capital held 1,800,000 shares of Immunocore worth $57.1M as of Q2 2026.
  • Vestal Point Capital sold 966,868 Immunocore shares in Q2 2026, an estimated $28.6M.
  • Immunocore made up 1.34% of Vestal Point Capital's portfolio in Q2 2026, its #26 holding.
  • Vestal Point Capital first reported a position in Immunocore in Q4 2025 and has held it in 3 quarters since.
  • Vestal Point Capital's Immunocore position peaked at $83.4M in Q1 2026.
  • 136 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.